

# Robin J Parks

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/4769745/robin-j-parks-publications-by-year.pdf>

**Version:** 2024-04-26

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

62

papers

3,087

citations

25

h-index

55

g-index

65

ext. papers

3,392

ext. citations

7.5

avg, IF

5.17

L-index

#	Paper	IF	Citations
62	Use of cell fusion proteins to enhance adenoviral vector efficacy as an anti-cancer therapeutic. <i>Cancer Gene Therapy</i> , <b>2021</b> , 28, 745-756	5.4	3
61	Delivery of Therapeutic Agents to the Central Nervous System and the Promise of Extracellular Vesicles. <i>Pharmaceutics</i> , <b>2021</b> , 13,	6.4	6
60	Label-free quantitative proteomic analysis of extracellular vesicles released from fibroblasts derived from patients with spinal muscular atrophy. <i>Proteomics</i> , <b>2021</b> , 21, e2000301	4.8	
59	Identification of human adenovirus replication inhibitors from a library of small molecules targeting cellular epigenetic regulators. <i>Virology</i> , <b>2021</b> , 555, 102-110	3.6	4
58	The genome position of a therapeutic transgene strongly influences the level of expression in an armed oncolytic human adenovirus vector. <i>Virology</i> , <b>2021</b> , 561, 87-97	3.6	
57	PKC-mediated phosphorylation of the diacylglycerol kinase MARCKS domain switches cell migration modes by regulating interactions with Rac1 and RhoA. <i>Journal of Biological Chemistry</i> , <b>2021</b> , 296, 100516	5.4	1
56	Fusion of Large Polypeptides to Human Adenovirus Type 5 Capsid Protein IX Can Compromise Virion Stability and DNA Packaging Capacity. <i>Journal of Virology</i> , <b>2020</b> , 94,	6.6	2
55	Antiviral Effects of Curcumin on Adenovirus Replication. <i>Microorganisms</i> , <b>2020</b> , 8,	4.9	5
54	Oncolytic Rhabdovirus Vaccine Boosts Chimeric Anti-DEC205 Priming for Effective Cancer Immunotherapy. <i>Molecular Therapy - Oncolytics</i> , <b>2020</b> , 19, 240-252	6.4	
53	Curcumin as an Antiviral Agent. <i>Viruses</i> , <b>2020</b> , 12,	6.2	46
52	Recent Advances in Novel Antiviral Therapies against Human Adenovirus. <i>Microorganisms</i> , <b>2020</b> , 8,	4.9	4
51	An Oncolytic Adenovirus Vector Expressing p14 FAST Protein Induces Widespread Syncytium Formation and Reduces Tumor Growth Rate. <i>Molecular Therapy - Oncolytics</i> , <b>2019</b> , 14, 107-120	6.4	10
50	Histone Deacetylase Inhibitor Suberoylanilide Hydroxamic Acid Suppresses Human Adenovirus Gene Expression and Replication. <i>Journal of Virology</i> , <b>2019</b> , 93,	6.6	15
49	p53 sensitizes chemoresistant non-small cell lung cancer via elevation of reactive oxygen species and suppression of EGFR/PI3K/AKT signaling. <i>Cancer Cell International</i> , <b>2019</b> , 19, 188	6.4	24
48	Development of a novel screening platform for the identification of small molecule inhibitors of human adenovirus. <i>Virology</i> , <b>2019</b> , 538, 24-34	3.6	8
47	p53 Promotes chemoresponsiveness by regulating hexokinase II gene transcription and metabolic reprogramming in epithelial ovarian cancer. <i>Molecular Carcinogenesis</i> , <b>2019</b> , 58, 2161-2174	5	18
46	Human adenoviral DNA association with nucleosomes containing histone variant H3.3 during the early phase of infection is not dependent on viral transcription or replication. <i>Biochemistry and Cell Biology</i> , <b>2018</b> , 96, 797-807	3.6	7

45	Building immune tolerance through DNA vaccination. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2018</b> , 115, 9652-9654	11.5	3
44	Survival Motor Neuron Protein is Released from Cells in Exosomes: A Potential Biomarker for Spinal Muscular Atrophy. <i>Scientific Reports</i> , <b>2017</b> , 7, 13859	4.9	10
43	The apolipoprotein C-III (Gln38Lys) variant associated with human hypertriglyceridemia is a gain-of-function mutation. <i>Journal of Lipid Research</i> , <b>2017</b> , 58, 2188-2196	6.3	25
42	mTORC1 activates SREBP-2 by suppressing cholesterol trafficking to lysosomes in mammalian cells. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2017</b> , 114, 7999-8004	11.5	47
41	Human adenovirus type 5 vectors deleted of early region 1 (E1) undergo limited expression of early replicative E2 proteins and DNA replication in non-permissive cells. <i>PLoS ONE</i> , <b>2017</b> , 12, e0181012	3.7	14
40	Adenoviral Vectors Armed with Cell Fusion-Inducing Proteins as Anti-Cancer Agents. <i>Viruses</i> , <b>2017</b> , 9,	6.2	8
39	Adenovirus-Mediated Expression of the p14 Fusion-Associated Small Transmembrane Protein Promotes Cancer Cell Fusion and Apoptosis In Vitro but Does Not Provide Therapeutic Efficacy in a Xenograft Mouse Model of Cancer. <i>PLoS ONE</i> , <b>2016</b> , 11, e0151516	3.7	7
38	Long-Term Blockade of Cocaine Self-Administration and Locomotor Activation in Rats by an Adenoviral Vector-Delivered Cocaine Hydrolase. <i>Journal of Pharmacology and Experimental Therapeutics</i> , <b>2016</b> , 357, 375-81	4.7	6
37	Temporal activation of XRCC1-mediated DNA repair is essential for muscle differentiation. <i>Cell Discovery</i> , <b>2016</b> , 2, 15041	22.3	22
36	Voluntary Running Triggers VGF-Mediated Oligodendrogenesis to Prolong the Lifespan of Snf2h-Null Ataxic Mice. <i>Cell Reports</i> , <b>2016</b> , 17, 862-875	10.6	24
35	Opening the window: The case for carrier and perinatal screening for spinal muscular atrophy. <i>Neuromuscular Disorders</i> , <b>2016</b> , 26, 551-9	2.9	7
34	Plasma butyrylcholinesterase regulates ghrelin to control aggression. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2015</b> , 112, 2251-6	11.5	77
33	Long-term reduction of cocaine self-administration in rats treated with adenoviral vector-delivered cocaine hydrolase: evidence for enzymatic activity. <i>Neuropsychopharmacology</i> , <b>2014</b> , 39, 1538-46	8.7	20
32	Physiologic and metabolic safety of butyrylcholinesterase gene therapy in mice. <i>Vaccine</i> , <b>2014</b> , 32, 4155-62	4.2	20
31	The adenovirus genome contributes to the structural stability of the virion. <i>Viruses</i> , <b>2014</b> , 6, 3563-83	6.2	37
30	A reduction in the human adenovirus virion size through use of a shortened fibre protein does not enhance muscle transduction following systemic or localised delivery in mice. <i>Virology</i> , <b>2014</b> , 468-470, 444-453	3.6	3
29	Supraphysiological expression of survival motor neuron protein from an adenovirus vector does not adversely affect cell function. <i>Biochemistry and Cell Biology</i> , <b>2013</b> , 91, 252-64	3.6	6
28	Snapshots: chromatin control of viral infection. <i>Virology</i> , <b>2013</b> , 435, 141-56	3.6	116

27	The role of chromatin in adenoviral vector function. <i>Viruses</i> , <b>2013</b> , 5, 1500-15	6.2	13
26	Chromatin structure of adenovirus DNA throughout infection. <i>Nucleic Acids Research</i> , <b>2012</b> , 40, 2369-76	20.1	62
25	Use of Cre/loxP recombination to swap cell binding motifs on the adenoviral capsid protein IX. <i>Virology</i> , <b>2011</b> , 420, 146-55	3.6	9
24	Rational design of murine secreted alkaline phosphatase for enhanced performance as a reporter gene in mouse gene therapy preclinical studies. <i>Human Gene Therapy</i> , <b>2011</b> , 22, 499-506	4.8	8
23	Assembly of helper-dependent adenovirus DNA into chromatin promotes efficient gene expression. <i>Journal of Virology</i> , <b>2011</b> , 85, 3950-8	6.6	33
22	Retargeting of adenovirus vectors through genetic fusion of a single-chain or single-domain antibody to capsid protein IX. <i>Journal of Virology</i> , <b>2010</b> , 84, 10074-86	6.6	36
21	Host cell detection of noncoding stuffer DNA contained in helper-dependent adenovirus vectors leads to epigenetic repression of transgene expression. <i>Journal of Virology</i> , <b>2009</b> , 83, 8409-17	6.6	32
20	Construction and characterization of adenovirus vectors. <i>Cold Spring Harbor Protocols</i> , <b>2009</b> , 2009, pdb.prot5013	11.7	47
19	DNA genome size affects the stability of the adenovirus virion. <i>Journal of Virology</i> , <b>2009</b> , 83, 2025-8	6.6	28
18	Adenovirus virion stability and the viral genome: size matters. <i>Molecular Therapy</i> , <b>2009</b> , 17, 1664-6	11.7	47
17	The inflammasome recognizes cytosolic microbial and host DNA and triggers an innate immune response. <i>Nature</i> , <b>2008</b> , 452, 103-7	50.4	746
16	Adenovirus protein IX: a new look at an old protein. <i>Molecular Therapy</i> , <b>2005</b> , 11, 19-25	11.7	70
15	Use of a murine secreted alkaline phosphatase as a non-immunogenic reporter gene in mice. <i>Journal of Gene Medicine</i> , <b>2005</b> , 7, 307-15	3.5	21
14	Helper-dependent adenoviral vectors containing modified fiber for improved transduction of developing and mature muscle cells. <i>Human Gene Therapy</i> , <b>2004</b> , 15, 179-88	4.8	19
13	Helper-dependent adenovirus vectors elicit intact innate but attenuated adaptive host immune responses in vivo. <i>Journal of Virology</i> , <b>2004</b> , 78, 5966-72	6.6	176
12	Activation of adenoviral gene expression by protein IX is not required for efficient virus replication. <i>Journal of Virology</i> , <b>2004</b> , 78, 5032-7	6.6	32
11	Use of adenovirus protein IX (pIX) to display large polypeptides on the virion--generation of fluorescent virus through the incorporation of pIX-GFP. <i>Molecular Therapy</i> , <b>2004</b> , 9, 617-24	11.7	92
10	Oncolytic adenovirus: getting there is half the battle. <i>Molecular Therapy</i> , <b>2003</b> , 8, 705-6	11.7	4

9	Alterations of plasma lipids in mice via adenoviral-mediated hepatic overexpression of human ABCA1. <i>Journal of Lipid Research</i> , <b>2003</b> , 44, 1470-80	6.3	74
8	Development of a gene therapy strategy for the restoration of survival motor neuron protein expression: implications for spinal muscular atrophy therapy. <i>Human Gene Therapy</i> , <b>2003</b> , 14, 179-88	4.8	28
7	Cancer therapy utilizing an adenoviral vector expressing only E1A. <i>Cancer Gene Therapy</i> , <b>2002</b> , 9, 321-9	5.4	25
6	Separating fact from fiction: assessing the potential of modified adenovirus vectors for use in human gene therapy. <i>Current Gene Therapy</i> , <b>2002</b> , 2, 111-33	4.3	112
5	Development of a FLP/frt system for generating helper-dependent adenoviral vectors. <i>Molecular Therapy</i> , <b>2001</b> , 3, 809-15	11.7	94
4	Improvements in adenoviral vector technology: overcoming barriers for gene therapy. <i>Clinical Genetics</i> , <b>2000</b> , 58, 1-11	4	42
3	Adenoviral vectors: prospects for gene delivery to the central nervous system. <i>Gene Therapy</i> , <b>1999</b> , 6, 1349-50	4	9
2	Effects of stuffer DNA on transgene expression from helper-dependent adenovirus vectors. <i>Journal of Virology</i> , <b>1999</b> , 73, 8027-34	6.6	81
1	Genomic DNA transfer with a high-capacity adenovirus vector results in improved in vivo gene expression and decreased toxicity. <i>Nature Genetics</i> , <b>1998</b> , 18, 180-3	36.3	566